Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Recruiting now NCT05196087
Run by University Health Network, Toronto · for 18 and older · All sexes
What this study is about
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.
Who can join (things the study team will check)
✅ You may be able to join if…
- Patients with histological confirmation of a solid tumor.
- Patients must have early stage or locally advanced disease that is planned for or have undergone curative treatment.
- Patient must be ≥ 18 years old.
- All patients must have signed and dated an informed consent form.
Where this trial is running
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Who to contact
Celeste Yu, MSc · 416-946-4501 · celeste.yu@uhn.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05196087.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.